Whalesbook
GLP-1 Market Sees Rapid Expansion
The global glucagon-like peptide-1 (GLP-1) market is experiencing rapid expansion, driven by both continued loyalty to innovator drugs and the strong market entry of generic alternatives. In April 2026, semaglutide drugs saw a month-on-month sales increase of 51% to ₹88 crore, boosting their share of the GLP-1 market to 40% from 33% in March, according to Pharmarack data. This market growth shows a dual trend: innovator drugs like Ozempic and Wegovy saw unit sales rise nearly 39% from 23,000 to 32,000, while generic semaglutide units surged 242%, from 40,000 to 137,000 units in the same period. This indicates a significant market expansion, with affordability increasing patient access. Eli Lilly's tirzepatide maintained its market lead, holding 55% of total GLP-1 sales and growing its monthly revenue by 6% to ₹121 crore in April.
Innovator Drugs Hold Their Ground
Despite over 25 generic semaglutide versions entering the market after patent expiry on March 20, 2026, innovator drugs are proving resilient. Doctors and some patients continue to prefer branded treatments, believing they offer better effectiveness and absorption. This loyalty has helped innovator semaglutide revenues stay stable, even as generics see rapid unit sales growth. In April, both innovator and generic semaglutide brands each generated ₹44 crore in revenue. This sustained preference highlights the value of established brands, even with cost considerations. Tirzepatide, sold as Mounjaro and Zepbound, continues to lead the market, backed by strong demand and Eli Lilly's ongoing development efforts.
Generics Fuel Market Growth With Affordability
The main driver of overall market growth is the availability of affordable generic options. The 242% jump in generic semaglutide unit sales shows a large increase in market reach, mainly due to lower prices and active marketing. This volume surge indicates the GLP-1 market is expanding, making these important treatments accessible to more patients. While innovator companies like Novo Nordisk and Eli Lilly are investing heavily in production to meet demand, the lower cost of generics poses a significant long-term challenge to pricing power.
Company Valuations: Eli Lilly vs. Novo Nordisk
Novo Nordisk (NVO) and Eli Lilly (LLY) are the leaders in the GLP-1 market, but their current valuations reflect different competitive outlooks. Eli Lilly has a market value near $918 billion with a trailing twelve-month price-to-earnings (P/E) ratio of about 34.6. Its stock has seen volatility, including a dip after reports of a liver failure case linked to its new oral GLP-1, Foundayo. Analysts mostly viewed this as an isolated event. The company recently reported excellent first-quarter 2026 results, with revenue of $19.8 billion, surpassing expectations and increasing its full-year forecast, largely driven by Mounjaro and Zepbound. Analysts remain mostly positive, with a consensus 'Moderate Buy' rating and average price targets near $1217. In contrast, Novo Nordisk, with a market value around $157 billion, trades at a much lower TTM P/E ratio of about 12.6. This lower valuation might suggest market worries about its competitive standing against Eli Lilly and growing generic competition. Novo Nordisk also reported strong Q1 2026 results, exceeding earnings expectations with $1.04 per ADR and improving its 2026 outlook, partly due to the successful launch of its Wegovy pill. However, analyst ratings have shifted to a 'Hold' rating, down from 'Moderate Buy' in recent months, according to 23 analysts. The overall pharmaceutical sector has a more positive outlook in 2026, driven by innovation. However, regulatory changes and tougher competition create a complex operating environment.
Pricing Pressure and Future Challenges
While innovator revenues remain strong, the large volume growth of generic semaglutide presents a clear threat. The market's expansion fueled by affordability suggests that pricing power for brand-name drugs is likely to decrease. Although generics for popular weekly injectables like Ozempic are not expected until around 2035, the current availability of semaglutide generics is already causing pricing pressure. Novo Nordisk's much lower P/E ratio compared to Eli Lilly might reflect this expected decrease in profit margins. Additionally, semaglutide products are on Medicare's list for drug price negotiations in 2027, suggesting future government-driven price changes. Eli Lilly faces scrutiny regarding recent liver failure reports linked to its oral Foundayo. Although this may be an isolated incident, it highlights risks associated with launching new drugs in a competitive market. Direct-to-consumer sales also offer notable discounts, further challenging standard pricing for both branded and generic drugs.
Future Outlook
Eli Lilly has raised its full-year 2026 revenue forecast to $82-85 billion and non-GAAP EPS to $35.50-$37.00, expecting continued strong demand for its GLP-1 drugs. Novo Nordisk has also improved its 2026 outlook. It expects a 4-12% decline in adjusted sales and operating profit at constant exchange rates, but this reflects stronger forecasts for GLP-1 sales, especially in obesity treatments. Analysts generally rate Eli Lilly a 'Moderate Buy' with a median price target around $1250. Novo Nordisk currently has a 'Hold' rating, suggesting a more cautious view on its short-term path amid changing market conditions.